It's not a viable competitor for Remestemcel-L in my opinion, not even close. Patient outcomes may be similar (great for the patients!), but proving efficacy and safety to the regulator does not happen overnight.
Mesoblast is so far ahead in terms of regulatory trials, efficacy and safety data, it simply doesn't compare. This stuff takes years of trials, legal, regulatory and IP matters.
SI recently stated that it takes nearly 15 years to bring biotech from credible science to regulatory approval; I don't doubt it.
It's not a viable competitor for Remestemcel-L in my opinion,...
-
- There are more pages in this discussion • 14,787 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
-0.073(5.78%) |
Mkt cap ! $1.353B | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.23 | $1.18 | $5.543M | 4.623M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 349869 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 82797 | 44 |
View Market Depth
| Last trade - 13.56pm 25/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |